Regorafenib
Quiénes somos
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
Evaluación de una combinación de regorafenib e irinotecán frente a regorafenib solo en pacientes con cáncer colorrectal metastásico
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
